Finding ways to maximize rest, accepting help, and prioritizing your own health alongside your babys creates better conditions for success with any intervention
Concerns over more severe adverse effects, including pancreatitis and possible thyroid tumors, may further deter both patients and healthcare providers from utilizing these medications
Retatrutide activates three, GLP-1, GIP, and glucagon
A lower-concentration build (2.5 mg/mL) spreads the dose across more units, so a one- or two-unit error is proportionally smaller at the cost of multi-fill draws later
Early evidence suggests it is generally well-tolerated, with most side effects being mild to moderate gastrointestinal symptoms (such as nausea, diarrhoea, or constipation)
Image Credit: DukiPH / Shutterstock.com Introduction Orforglipron is an orally bioavailable next-generation glucagon-like peptide 1 (GLP-1) receptor agonist (GLP-1RA) that has emerged as a potential alternative to injectable agents like semaglutide based on early Phase 1, 2, and 3 clinical trials demonstrating glucose-lowering and weight-loss efficacy without the need for injection-based delivery
